Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02595437 · ClinicalTrials.gov registry record · Phase 1
Triferic Pediatric Pharmacokinetic Protocol
A Phase 1 study, sponsored by Rockwell Medical Technologies.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT02595437 is a Phase 1 study that has completed, run by Rockwell Medical Technologies. The registered enrollment target is 22 participants.
The verdict
NCT02595437, a Phase 1 study, has completed, sponsored by Rockwell Medical Technologies.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
The main purpose is to determine the pharmacokinetics (PK) of Triferic iron administered intravenously in pediatric patients with chronic kidney disease on chronic hemodialysis (CKD-5HD). It is an open-label, two-period sequential dosing study.
Interventions
- DRUG Triferic
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2015-11-01 |
| Est. Completion | 2017-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02595437
The ClinicalTrials.gov registry entry for NCT02595437 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rockwell Medical Technologies, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Triferic is the first listed.
NCT02595437 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02595437 about?
NCT02595437 is a clinical study titled "Triferic Pediatric Pharmacokinetic Protocol". The main purpose is to determine the pharmacokinetics (PK) of Triferic iron administered intravenously in pediatric patients with chronic kidney disease on chronic hemodialysis (CKD-5HD). It is an open-label, two-period sequential dosing study.
What is the current status of trial NCT02595437?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2015-11-01. Estimated completion is 2017-01.
What interventions are being tested in trial NCT02595437?
The interventions under investigation include: Triferic (DRUG).
Who is sponsoring clinical trial NCT02595437?
This trial is sponsored by Rockwell Medical Technologies, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.